Search 

Swiss- Israeli based company, fuses the know how of specialists in the pahrmacology and delivery fields with the aim to bring to the market novel drugs based on cannabinoid molecules as stand alone, and synergistic combinations with proper drug delivery technologies

CytoReason is a big-data analytics company specializing in immunotherapy using its proprietary Cell-Centered Model. The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy datasets. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions that extend beyond the data provided by the customer and can be translated to valuable IP. CytoReason’s technology has yielded 2 pending patents, 7 scientific collaborations and 12 peer reviewed publications

immuno-oncology

inflammatory diseases

inflammatory autoimmune 

big data

biomarker

Our technology integrates different genomic and proteomic measurements with clinical data and predicts cellular immunological pathways.

The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy trials. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions. The system generates immune interaction networks that extend beyond the data provided by the customer.  

CytoReason is generating valuable IP and Know-How for biotech and pharmaceutical companies, universities and research institutions throughout their basic research, drug development, and clinical trials. 

Dolopharm is a drug development company from Charité, Berlin, with a focus on GPCR-targeted therapies. Our first pipeline candidate NFEPP for the treatment of severe acute and chronic pain has shown impressive performance in several pre-clinical trial models. In contrast to standard medications, such as opioids, NFEPP avoids drug addiction, respiratory depression, constipation and other known side effects thus representing a potential breakthrough medication for many pain related indications. 

Drug Development

New Drugs

Pain therapy

Start-up seeking for initial financing

We are currently looking for investors to finance our clinical phase I studies in post-operative pain treatment after knee surgery. So, feel free to talk to us and find out, how to join this outstanding investment opportunity.

Gynotech is a developer of SMAT solutions for uro-gynecology conditions such as vaginal prolapse  and urinary incontinence.

Gynotech has developed the first smart, dynamic pessary that automatically adjust its size in response to the changing intr-abdominal pressures and thus provides a much better prevention of prolapse and urinary leakages.

The device is still at a development stage.

Hylomorph is a newly formed medical device company based in Switzerland with a breakthrough technology to improve the biocompatibility of medical implants. Upon implantation, devices such as cardiac implantable electronic devices or breast implants are perceived as a foreign body resulting in the formation of fibrotic (scar) tissue around the implant over time. This can lead to severe complications both for patient and surgeon during revision surgery resulting in additional costs of care.

Hylomorph has developed a novel material from biocellulose which has a unique macro and micro morphology disrupting both protein and fibroblast adhesion, blocking the process of fibrotic capsule formation.  This material can be formed into a variety of shapes which can be placed around the implantable device, both acting as a physical barrier and an active anti-fibrotic membrane.

Hylomorph is applying this technology to the two largest implantable medical device markets: cardiac implantable electronic devices, and breast implants, aiming to reduce significantly the clinical and economic problems associated with fibrotic capsule formation. Clinical trials will commence in 2018 with CE mark and FDA 510k clearance planned for 2020.     

Series A planned for Q2 2018

ID-NEST is currently developping a new, disruptive way to rebuild vascular bifurcations. Targeted indications are Aortic Arch Aneurysms and Compressed Veins. Our technology focuses on a patented way to connect 2 self-expandable stents on site, in order to restore native vessel capacities. 

endograft, stent graft, deep vein thrombosis, post-thrombotic syndrom, compressed veins, aortic arch aneurysms, self-expanding stents

Experienced and complementary team.

Scientific Committee comprises Pr Nabil Chakfé (Strasbourg), Dr Philippe Nicolini (Lyon), Pr Gerard O'Sullivan (Galway), Pr Stephen Black (London), Pr Armando Mansilha (Porto), Dr Olivier Hartung (Marseille).

Operational Team comprises:

. C. Tézenas du Montcel, CEO, MBA, 20+ years of experience at Management level in the Vascular Devices industry,

. William Wiecek, COO, 25+ years in the Medical Devices Industry. QA/RA specialist.

We're looking at a 10 millions € need, with a first slice of 2 millions € now to fund the Technological Development, followed by a 8 millions € slice to fund the clinicals

Since more than 450mio people have a bad mental being affecting their capacity ‘’to work and to love’’, our next step is to apply our technology to a life coaching app combining psychological and genetic data analysis coupled with artificial intelligence. 

At your fingertip, you will have access to our existing network of coaches and specialists who can help you improve your overall wellbeing by understanding the real you.

DNA, PSYCHOLOGY, NATURE, NURTURE, COACHING, BIOTECH, GENETIC TEST, ASSESSMENT, INNOVATION, PERSONALISED, FUTURE

Retinitis Pigmentosa (RP), Leber’s Congenital Amaurosis (LCA) and Stargardt’s Disease (STGD) are rare eye diseases leading to severe vision impairment or blindness.  Within the eye, they cause degeneration of the photoreceptors responsible for conversion of light into signals to be sent to the brain. The conditions are inherited and caused by ~250 different gene mutations. They affect a combined 450,000 people within the EU, Japan and the US.
To date, no treatment is available for RP, LCA and STGD.
Mireca wants to develop drug candidate LP–DF 003 which uses a novel approach for the treatment of the conditions. In contrast to current gene therapies, which address specific gene mutations, Mireca’s approach is significantly broader and assumed suitable to target at least one third of the various gene mutations.
Based on the promising outcomes of the EU (FP7) funded DRUGSFORD project, Mireca benefits from completed pre-clinical pharmacology and initial safety testing, an existing orphan drug designation granted by the EMA, a GMP-compliant production process, 3 patent applications and exclusive licensing agreements.
Beyond currently planned product developments, Mireca has access to a platform technology for the potential treatment of several neurodegenerative diseases.
Mireca has been set up as a German limited liability company (“GmbH”) located in Tuebingen (~40 kilometers south of DE-Stuttgart). Mireca’s experienced international management team combines broad and deep scientific as well as business experience.
Mireca wants to transition LP-DF003 into clinical studies and aims to obtain market authorizations for RP, LCA and STGD treatment products starting in the year 2024.

Mireca´s lead compound is a small molecule intended for the treatment of rare and currently untreatable forms of hereditary blindness.

Mireca currently runs a Series A funding round to initiate clinical studies.

Musli Thyropeutics is a clinical stage pharmaceutical company addressing high-grade cancers. The company's patented fix-dose combination is based on recent scientific findings. Musli is targeting Glioblastoma Multiforme and Brain Metastases as-well-as Lung cancer and other aggressive high-grade cancers. Musli is preparing for Phase 2/3 clinical trials starting in 2018. Our innovative adjunct approach to current standard of care is expected to facilitate quick penetration to some of the largest markets in oncology, composing a multi-billion opportunity.

Nanosynex is saving lives from superbugs.

Our fight starts by diagnosing bacterial resistance to antibiotics in record time, using microfluidics.

Our test will help doctors determine the most appropriate antibiotic treatment for their patients and provide same-day results, which will reduce the spread of resistant bacteria and significantly lower the burden on healthcare costs.

This revolutionary scientific development is supported by a Proof of Concept from the lab of Prof. Levenberg, Dean of the Technion Biomedical Engineering Faculty.

Antimicrobial resistance 

Rapid test 

In vitro diagnostics

Microfluidics 

Technion Technology Transfer

A test to check bacterial resistance composed of disposable cards and a benchtop reader